Lipaxan (Fluvastatin Sodium)

Fluvastatin Sodium acts on lipid metabolism to lower cholesterol levels in several clinical settings.

• Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol, improving lipid profile.
• Hyperlipidemia: decreases triglycerides and raises HDL‑cholesterol as part of comprehensive lipid management.
• Cardiovascular risk reduction: lowers incidence of myocardial infarction and stroke in patients with elevated LDL‑cholesterol.

• Fluvastatin Sodium selectively inhibits HMG‑CoA reductase, the key enzyme that catalyzes the conversion of HMG‑CoA to mevalonate in the hepatic cholesterol biosynthetic pathway. By blocking this rate‑limiting step, hepatic cholesterol synthesis declines, prompting up‑regulation of LDL receptors on hepatocyte surfaces, which enhances clearance of circulating LDL particles and reduces plasma cholesterol concentrations.

Fluvastatin Sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Abdominal pain: discomfort in the stomach area.
• Myalgia: muscle aches without weakness.
• Elevated liver enzymes: mild increase in ALT or AST.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown that can lead to renal failure.
• Acute liver injury: marked elevation of hepatic enzymes with jaundice.
• Severe allergic reaction: rash, angioedema or anaphylaxis.
• Myopathy with weakness: significant muscle pain accompanied by reduced strength.

Before initiating therapy with Fluvastatin Sodium, several safety considerations should be reviewed.

• Baseline liver assessment: obtain ALT/AST levels prior to treatment and monitor periodically.
• Muscle symptom monitoring: advise patients to report unexplained muscle pain, tenderness or weakness.
• Avoid in active liver disease: contraindicated in patients with persistent hepatic impairment.
• Caution with CYP3A4 inhibitors: dose may need adjustment when co‑administered with strong inhibitors.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Fluvastatin Sodium has a potential for drug‑drug interactions that may require dose modification or avoidance.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase statin exposure and risk of myopathy.
• Gemfibrozil: synergistic effect on muscle toxicity.
• Cyclosporine: elevates plasma concentrations of fluvastatin.
• HIV protease inhibitors: may raise statin levels substantially.

Moderate Interactions (Monitor Closely)

• Warfarin: fluvastatin can enhance anticoagulant effect, requiring INR monitoring.
• Antacids containing aluminum or magnesium: may reduce oral absorption of the statin.
• Niacin: combined therapy can increase risk of hepatotoxicity.
• Digoxin: possible increase in digoxin serum levels.